AR057253A1 - Anticuerpos anti-ox40l y metodos que los utilizan - Google Patents

Anticuerpos anti-ox40l y metodos que los utilizan

Info

Publication number
AR057253A1
AR057253A1 ARP060105564A ARP060105564A AR057253A1 AR 057253 A1 AR057253 A1 AR 057253A1 AR P060105564 A ARP060105564 A AR P060105564A AR P060105564 A ARP060105564 A AR P060105564A AR 057253 A1 AR057253 A1 AR 057253A1
Authority
AR
Argentina
Prior art keywords
methods
ox40l antibodies
ox40l
antibodies
compositions
Prior art date
Application number
ARP060105564A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR057253A1 publication Critical patent/AR057253A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente proporciona anticuerpos anti-OX40L y composiciones que los comprenden y métodos de uso de estos compuestos.
ARP060105564A 2005-12-16 2006-12-15 Anticuerpos anti-ox40l y metodos que los utilizan AR057253A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75137705P 2005-12-16 2005-12-16

Publications (1)

Publication Number Publication Date
AR057253A1 true AR057253A1 (es) 2007-11-21

Family

ID=38616368

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105564A AR057253A1 (es) 2005-12-16 2006-12-15 Anticuerpos anti-ox40l y metodos que los utilizan

Country Status (18)

Country Link
US (2) US7812133B2 (es)
EP (1) EP1973949A2 (es)
JP (1) JP2009519718A (es)
KR (1) KR20080080639A (es)
CN (1) CN101374865A (es)
AR (1) AR057253A1 (es)
AU (1) AU2006343459A1 (es)
BR (1) BRPI0621065A2 (es)
CA (1) CA2633602A1 (es)
CR (1) CR10069A (es)
EC (1) ECSP088543A (es)
IL (1) IL191820A0 (es)
MA (1) MA30153B1 (es)
NO (1) NO20083147L (es)
RU (1) RU2426744C2 (es)
TW (1) TW200732349A (es)
WO (1) WO2007133290A2 (es)
ZA (1) ZA200804868B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
EP2041756B1 (en) 2006-07-14 2015-05-13 FEI Company A multi-source plasma focused ion beam system
KR20100014588A (ko) * 2007-02-27 2010-02-10 제넨테크, 인크. 길항제 ｏｘ40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도
US20090309617A1 (en) * 2007-08-24 2009-12-17 Ye Fang Biosensor antibody functional mapping
WO2009141239A1 (en) * 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
US8518405B2 (en) * 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
EP3309176B1 (en) 2009-12-14 2025-10-01 Ablynx N.V. Immunoglobulin single variable domain antibodies against ox40l, constructs and their therapeutic use
WO2012015696A1 (en) * 2010-07-26 2012-02-02 Baylor Research Institute Thymic stromal lymphopoietin (tslp) and ox40 ligand in cancer
CA2809089C (en) 2010-08-23 2018-12-18 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
HUE038848T2 (hu) 2011-04-21 2018-11-28 Bristol Myers Squibb Co CD40-antagonista antitest polipeptidek
CA2845810C (en) * 2011-08-23 2017-03-28 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
EP3043810B1 (en) 2013-09-09 2019-10-23 CanImGuide Therapeutics AB Immune system modulators
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP2017165652A (ja) * 2014-06-30 2017-09-21 国立大学法人東北大学 新規抗ヒトｏｘ４０リガンド抗体、及びこれを含む抗インフルエンザ薬
AU2015301338C1 (en) * 2014-08-04 2021-07-22 Baylor Research Institute Antagonistic anti-OX40L antibodies and methods of their use
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
US9434785B1 (en) 2015-04-30 2016-09-06 Kymab Limited Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
KR20250005465A (ko) * 2015-03-03 2025-01-09 키맵 리미티드 항체, 용도 및 방법
WO2016144650A1 (en) 2015-03-06 2016-09-15 Canimguide Therapeutics Ab Immune system modulators and compositions
SG11201708804WA (en) 2015-05-07 2017-11-29 Agenus Inc Anti-ox40 antibodies and methods of use thereof
CN108883173B (zh) 2015-12-02 2022-09-06 阿吉纳斯公司 抗体和其使用方法
DE102016105069A1 (de) 2016-03-18 2017-09-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Antivirale Immuntherapie durch Membranrezeptorligation
AU2016402264B2 (en) * 2016-04-15 2024-08-22 Pontificia Universidad Católica De Chile Pharmaceutical composition for reducing the symptoms and disease of the respiratory infection caused by human metapneumovirus (HMPV), which comprises at least one agent that neutralises the function of the TSLP and/or TSLPR and/or OX40L and/or CD177 molecules, and a pharmaceutically acceptable excipient, and the use thereof
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11858996B2 (en) 2016-08-09 2024-01-02 Kymab Limited Anti-ICOS antibodies
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
US12605469B2 (en) 2017-10-02 2026-04-21 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
EP3713958A4 (en) 2017-11-24 2021-11-03 Eucure (Beijing) Biopharma Co., Ltd ANTI-OX40 ANTIBODIES AND USES THEREOF
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
GB202012331D0 (en) * 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
CN114437228B (zh) * 2020-10-30 2024-02-06 中国科学院生物物理研究所 一种il-2与抗体亚单位构成的双功能融合蛋白
TWI905133B (zh) * 2020-12-09 2025-11-21 南韓商怡諾安有限公司 抗-OX40L抗體、抗OX40L和抗-TNFα雙特異性抗體及其用途
WO2022123293A1 (ko) * 2020-12-09 2022-06-16 에이치케이이노엔 주식회사 항 OX40L 항체, 항 OX40L 및 항 TNFα 이중 특이성 항체 및 이들의 용도
US20230235069A1 (en) * 2021-08-10 2023-07-27 Kymab Limited Treatment of atopic dermatitis
KR20240139085A (ko) * 2022-02-09 2024-09-20 펫메딕스 리미티드 치료 항체
WO2025090570A1 (en) * 2023-10-23 2025-05-01 Abcellera Biologics Inc. Anti-ox40l antibodies and methods of use
TW202540204A (zh) * 2024-01-26 2025-10-16 西班牙商阿爾米雷爾有限公司 雙特異性分子及使用其的治療方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
JP3914342B2 (ja) 1997-09-25 2007-05-16 武田薬品工業株式会社 ｇｐ３４結合阻害物を有効成分として含有する医薬組成物
JP2003535592A (ja) * 2000-06-06 2003-12-02 アイデック ファーマスーティカルズ コーポレイション ヒトｇｐ３９に対する非アゴニスト抗体、含有する組成物、およびその治療的使用
FR2822846B1 (fr) 2001-04-03 2004-01-23 Technopharm Procede de preparation et de selection d'anticorps
GB0123276D0 (en) 2001-09-27 2001-11-21 Imp College Innovations Ltd Uses of agents that bind immune-system components
JP3926596B2 (ja) 2001-09-28 2007-06-06 独立行政法人科学技術振興機構 Ｏｘ４０ｌ遺伝子を導入した自己免疫疾患モデル非ヒト哺乳動物
WO2003059245A2 (en) * 2001-12-18 2003-07-24 J & J Research Pty Ltd Method of treating asthma
IL164376A0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
JP2006508056A (ja) 2002-08-28 2006-03-09 イミュネックス・コーポレーション 心臓血管疾患を治療するための組成物および方法
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
WO2005094879A2 (en) 2004-03-23 2005-10-13 Amgen, Inc. Monoclonal antibodies specific for human ox40l (cd 134l)
JP2006081061A (ja) 2004-09-13 2006-03-23 Alpine Electronics Inc 音声出力装置及び音声／映像出力装置
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
KR20100014588A (ko) 2007-02-27 2010-02-10 제넨테크, 인크. 길항제 ｏｘ40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도

Also Published As

Publication number Publication date
KR20080080639A (ko) 2008-09-04
RU2008129111A (ru) 2010-01-27
IL191820A0 (en) 2008-12-29
TW200732349A (en) 2007-09-01
WO2007133290A8 (en) 2008-03-27
US7812133B2 (en) 2010-10-12
BRPI0621065A2 (pt) 2011-11-29
AU2006343459A1 (en) 2007-11-22
RU2426744C2 (ru) 2011-08-20
US20090053230A1 (en) 2009-02-26
WO2007133290A2 (en) 2007-11-22
MA30153B1 (fr) 2009-01-02
CN101374865A (zh) 2009-02-25
WO2007133290A3 (en) 2008-01-10
CA2633602A1 (en) 2007-11-22
JP2009519718A (ja) 2009-05-21
NO20083147L (no) 2008-09-16
CR10069A (es) 2008-10-10
US20100272738A1 (en) 2010-10-28
EP1973949A2 (en) 2008-10-01
ECSP088543A (es) 2008-07-30
ZA200804868B (en) 2009-10-28

Similar Documents

Publication Publication Date Title
AR057253A1 (es) Anticuerpos anti-ox40l y metodos que los utilizan
CR20150088A (es) Anticuerpos anti-notch1 nrr
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
AR057237A1 (es) Metodos y composiciones para actuar sobre la poliubiquitina
AR059096A1 (es) Anticuerpos anti- efrina -b2 y metodos que usan estos
AR059851A1 (es) Anticuerpos de la egfl7 y metodos de uso
HN2011000357A (es) Composiciones y metodos para anticuerpos que que se dirigen a la proteina de complemento c5
CR10372A (es) Anticuerpos anti-tat226 e inmunoconjugados
ECSP099619A (es) Anticuerpos anti-robo4 y sus usos
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
CR20140180A (es) Inhibidores macrocíclicos de serina proteasas de hepatitis c
CO6450665A2 (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
HN2008000179A (es) Compuestos triciclicos,composiciones y procedimientos
ECSP077316A (es) Compuestos imidazo-3-il-amina bicíclicos sustituidos
ECSP11011344A (es) Nuevos anticuerpos anti-?5?1 y sus usos
CR11274A (es) Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
AR063532A1 (es) Anticuerpos e inmunoconjugados y sus usos
ECSP088924A (es) Anticuerpos e inmunoconjugados y sus usos
AR066042A1 (es) Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9)
NI200900081U (es) Anticuerpos agonistas de trkb y sus usos.
GT201000047A (es) Mejoras en compuestos organicos o relacionadas con los mismos
NO20074277L (no) Kinnolinforbindelser og anvendelse derav som lever X reseptor modulatorer
ECSP077378A (es) Isoxazoles sustituidos como fungicidas
CR20110555A (es) Anticuerpos anti-fgfr3 y métosos que los utilizan
CY1115900T1 (el) Αντισωματα αντι-ephb4 και μεθοδοι χρησης αυτων

Legal Events

Date Code Title Description
FA Abandonment or withdrawal